Although widely

recognized for many years, there are currently only a few drugs available for influenza treatment. The only licensed existing drugs are the adamantane, amantadine and rimantadine, which act specifically against influenza A/H1N1 (2009) virus by blocking the ion channel of the M2 protein.2 However, these compounds are not widely used owing to their limited spectrum of activity and adverse side effects and also because of the rapid emergence of resistant virus during treatment. Nowadays the viral strains are highly resistant against antiviral drugs and moreover producing novel strains. Assisted antiviral drugs are mainly targeting the viral M2 ion channels, neuraminidase and hemagglutinin click here are still not sufficient to handle the viral infection, therefore there is a need to identify effective anti-influenza viral agent.3 and 4 Pyrimido quinoline nuclei have been a source of great interest to organic, medicinal and materials scientists over many years, which is present in a number of biologically active organic compounds which exhibit, antibacterial5 anticancer6 anti-inflammatory

activity and antioxidant.7 Moreover, the increasing biological importance of pyrimido quinoline derivatives particularly in the field of chemotherapy, prompted us to develop and identify the new molecules so far explore antiviral activity. In this study we have analyzed and explored the compound 4-methyl pyrimido (5, 4-c) quinoline-2,5(1H, 6H)-dione, and it could be a lead to develop new interesting drugs with an improved antiviral Epigenetics inhibitor activity

for influenza viral replications. The pyrimido quinoline compound synthesis method follows previously reported by Sankaran et al.8 To the corresponding 4-hydroxy-3-acyl quinoline-2-one (0.01 mmol), urea (0.01) and a catalytic amount of sodium acetate (0.01 mmol) in ethanol was refluxed over a period of 7–8 h. After completion of the reaction as inferred by TLC excess ethanol was removed, the mixture was cooled to room temperature and poured into 500 gms of crushed ice. The precipitate thus obtained was recuperated by filtration, the residue subjected to column chromatography on silica gel using petroleum ether, ethyl acetate (3:3 v/v) afforded the product 4-methyl pyrimido (5, 4-c) quinoline-2,5(1H, 6H)-dione in 85% yield. mp 225 °C; IR (KBr) ν (cm−1) 3741.29, 2883.12, 2360.18, ADP ribosylation factor 1663.71, 1250.00, 974.89, 751.67, 674.65. 1H NMR (DMSO-d6, 400 MHz) δ 11.53 (1H, s, NH) 8.56 (1H, s, NH), 7.96 (1H, d, J = 7.96 Hz, Ar–H) 7.66 (1H, t, J = 7.28 Hz Ar–H), 7.19–7.28 (5H, m, Ar–H), 2.70 (3H, s, CH3), 13C NMR (DMSO-d6, 400 MHz) 205.98, 174.75, 161.20, 145.20, 145.70, 135.05, 124.71, 121.99, 115.46, 113.42, 105.78, 30.60 Anal. Calcd for C12H9N3O2 (227.07): C, 63.43; H, 3.99; N, 18.49. Found: C, 63.50; H, 3.42; N, 18.45 ( Fig. 1 a & b). Influenza A/H1N1 (2009) viral strain was obtained from King Institute of Preventive Medicine & Research, Virology Department, Chennai.